Related Experiment Video

Updated: Mar 6, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

8.0K

MicroRNA-133 mediates cardiac diseases: Mechanisms and clinical implications

Yi Liu1, Yan Liang1, Jin-Fang Zhang2

  • 1Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong Medical University, Zhanjiang 524023, Guangdong, China.

Experimental Cell Research
|March 22, 2017
PubMed

Insights

MicroRNAs (miRNAs), specifically miR-133, are crucial in muscle and heart function. Aberrant miR-133 expression is linked to cardiac disorders, suggesting its potential as a diagnostic and therapeutic target.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cardiology

Background:

  • MicroRNAs (miRNAs) are small non-coding RNAs regulating gene expression post-transcriptionally.
  • miR-133 is notably abundant in muscle and myogenic cells.
  • Dysregulation of miR-133 is implicated in the pathogenesis of cardiac disorders.

Purpose of the Study:

  • To review the regulatory functions of miR-133 in cardiac disorders.
  • To elucidate the underlying molecular mechanisms.
  • To assess miR-133 as a potential biomarker and therapeutic agent for heart conditions.

Main Methods:

  • Literature review of studies on miR-133 and cardiac disorders.
  • Analysis of regulatory pathways involving miR-133.
  • Synthesis of evidence on diagnostic and therapeutic potential.

Main Results:

  • miR-133 plays a significant role in the development of cardiac hypertrophy and heart failure.
  • Specific molecular mechanisms of miR-133 action in the heart have been identified.
  • Evidence supports miR-133's involvement in disease progression.

Conclusions:

  • miR-133 is a key regulator in cardiac pathophysiology.
  • Understanding miR-133's role offers insights into disease mechanisms.
  • miR-133 holds promise as a diagnostic and therapeutic tool for cardiac disorders.
Keywords:
Cardiac hypertrophyHeart diseaseMiR-133MicroRNAsTarget genes

More Related Videos

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.6K
CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.9K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.4K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
274
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
469
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
390
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
688